Project Grant R01CA303470
Award Date 8/25/25
Completion Date 7/31/30
Dollars Obligated $717K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award of $402,600, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP complex for the treatment of acute myeloid leukemia (AML). The Sloan-Kettering Institute for Cancer Research, a leading nonprofit cancer research organization, is the awardee for this 5-year project, which commenced on April 3, 2025. The goal is to advance these...
- This Project Grant award of $194,013 from the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), is supporting the development of a new monoclonal antibody-based tool to treat small cell lung cancer (SCLC). The University of Southern California (USC) is leading this 2-year effort to leverage an immune response against a specific protein modification, isoaspartylation of the ELAVL4 protein, which is expressed on SCLC tumor cells. The goal is to...
- The Sloan-Kettering Institute for Cancer Research was awarded a $736,168 Project Grant by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) on August 1, 2025. The grant supports the development of novel antibody-drug conjugates (ADCs) that can deliver potent radiosensitizing payloads to antigen-bearing tumor cells, with the goal of improving the therapeutic index of radiotherapy. Key aspects of the research include: Creating first-in-class ADCs with DNA damage response...
- The U.S. National Cancer Institute (NCI) awarded a $191,675 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The University of Texas Southwestern Medical Center (UT Southwestern) in Dallas, Texas. The grant will fund research to investigate the role of Jumonji lysine demethylases, a family of epigenetic enzymes, as potential druggable targets for treating small cell lung cancer (SCLC), including SCLC that has developed resistance to existing chemotherapies. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- The National Cancer Institute (NCI) awarded a Project Grant, CFDA 93.395 "Cancer Treatment Research", to the University of North Carolina at Chapel Hill (UNC-CH) in the amount of $627,456 on December 1, 2024. The purpose of this 5-year grant is to conduct a Phase I clinical trial evaluating the safety and efficacy of a CSPG4-targeted CAR-T cell therapy for the treatment of head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum-based chemotherapy and PD-1...
- The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...
- This $1,108,391.72 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Leland Stanford Junior University supports a 2-year training plan and 5-year research program to study chimeric antigen receptor (CAR) T cell therapies for large B-cell lymphoma (LBCL). The key objectives are to: 1) define the most therapeutically relevant CAR T cell subsets in LBCL patients, and 2) overcome immune suppression mechanisms of resistance to CAR T cell therapy...
- The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research into detecting and eliminating drug-tolerant persister cells in small cell lung cancer (SCLC). The $424,836 award, granted on April 11, 2025, will fund a collaborative effort led by the University of Texas MD Anderson Cancer Center to investigate the mechanisms underlying SCLC's high initial response and rapid emergence of drug resistance. The project aims to technically enrich...